Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

Breast Cancer Now said olaparib will be an ‘valuable alternative’ for patients with a certain type of secondary breast cancer ...

Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of Ontario’s Cancer ...

Cancer is a disease of the genome, according to Dr. Elli Papaemmanuil, computational oncologist at MSK. By looking at the ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...